The DEA realizes cannabis demand is only going to grow…
On average, 130 Americans die each day from an opioid overdose.
It’s a national crisis, but small towns have been hit the hardest.
In those remote locations, “Main Street” is struggling, there are not enough well-paying jobs, and access to higher education is out of reach because it’s too expensive.
But there are plenty of pills.
From 2006 to 2012, 17 million opioid prescriptions flooded the streets of Russell County in Virginia, which has a population of less than 30,000 people. Norton, Virginia, which has a population of just over 4,000, had over 8 million pills shipped to it during that same time.
There are a lot of reasons why the opioid epidemic has spread but, diving deeper into the issue, you start to see that there’s also been a lack of options for those who need legitimate pain relief.
Many would gladly try cannabis-based medicine to help with back aches or arthritis, but their state government has made it difficult to obtain a medical card through or doesn’t even allow medical cannabis.
Fortunately, things are changing.
The DEA Orders More Cannabis
Originally the Drug Enforcement Administration (DEA) wanted 72.5 million grams of oxycodone to be manufactured, but it decreased that final quota to 67.5 million.
That’s still a lot of an opioid being sold, but at least it is a reduction.
In comparison, the DEA authorized a 30% increase in cannabis cultivation from the previous year for 2020. The increase in cannabis cultivation is because of “estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks,” according to the DEA.
The more medical and scientific research there is, the more we can unlock the powerful compounds in the cannabis plant to potentially treat everything from headaches to opioid addiction.
A study published November 25 in the Journal of Pain found that inhaled cannabis reduces self-reported headache severity by 47.3% and migraine severity by 49.6%.
This cannabis sector is projected to hit $22 billion over the next 12-36 months. Learn how you could profit off this 3,622% jump in sales by clicking here.
In another development, Green Point Research just formed a new partnership with Florida State University to conduct a study analyzing Green Point’s Satividol CBD softgel capsule.
The hope is for the company to create an FDA-approved capsule that could replace ibuprofen to treat acute pain.
Finally, new research from the British Columbia Centre on Substance Use and the University of British Columbia found that of those interviewed who reported chronic pain and who used cannabis daily were half as likely to use illicit opioids when compared to those who did not.
Reaching Full U.S. Legalization
The U.S. government realizes it can’t keep fighting the will of people, and full U.S. cannabis recreational legalization is closer than ever before.
That will lead to everyone finally being able to decide for themselves if they want to utilize cannabis-based medicine.
I’m glad you are here with us to witness these moments.
Executive Director, National Institute for Cannabis Investors
P.S. U.S. legalization will be a big topic for 2020, but we can’t forget about our neighbors up north. Canada 2.0 is going to kick off in less than a month, and our estimates show it could release $3.9 billion – or even as much as $7.8 billion – into this growing market. One of our staff members wanted to pick Greg’s brain about the best way to profit, and Greg wanted to make sure everyone saw his answer. Just click here to hear more about why stock prices could skyrocket 200%… 400%… or even 1,000%.
9 responses to “DEA Decreases Quota for Oxycodone and Increases Cannabis Quota by 30%”
December 03 2019